Ironwood Pharmaceuticals Inc (IRWD)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $799.61M
Last updated: Nov 17, 2026 at 11:06 AM ET
Ironwood Pharmaceuticals Inc (IRWD) Stock Forecast
Analysts expect Ironwood Pharmaceuticals (IRWD) to earn $1.30 per share in the fiscal year ending Dec 31, 2026, on revenue of $493.63M. Of 4 analysts, 2 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 2.25, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 50% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 25.0% |
| Buy | 1 | 25.0% |
| Hold | 2 | 50.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 20.8% and revenue estimates rise 2.1%.
- Fiscal year ending Dec 31, 2026
- $1.30
- EPS consensus, revenue $493.63M
- Fiscal year ending Dec 31, 2027
- $1.57
- EPS consensus, revenue $504.23M
- Next report
- Feb 23, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.30 | $1.28 to $1.32 | 2 | $493.63M | $489.10M to $497.80M | 3 |
| Dec 31, 2027 | $1.57 | $1.36 to $1.82 | 3 | $504.23M | $470.30M to $530.60M | 4 |
Quarterly Estimates
The EPS consensus falls from $0.37 for the quarter ending Dec 31, 2026 to $0.31 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.37 | $0.33 to $0.41 | 6 | $143.75M | $133.87M to $152.46M | 6 |
| Mar 31, 2027 | $0.31 | $0.26 to $0.35 | 2 | $108.90M | $108.90M to $108.90M | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 7.4% from $1.21.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $1.30 | $1.21 | $1.21 | $1.21 | $1.21 | +7.4% |
| Fiscal year ending Dec 31, 2027 | $1.57 | $1.50 | $1.50 | $1.50 | $1.50 | +4.4% |
| Quarter ending Mar 31, 2027 | $0.31 | $0.30 | $0.30 | $0.30 | $0.30 | +3.4% |
Frequently Asked Questions About IRWD
What is the IRWD stock forecast?
Consensus analyst estimates put Ironwood Pharmaceuticals's EPS at $1.30 for the fiscal year ending Dec 31, 2026, on revenue of $493.63M. The consensus rating from 4 analysts is Buy.
How do analysts rate IRWD stock?
Of 4 analysts covering Ironwood Pharmaceuticals, 1 rates it Strong Buy, 1 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from IRWD next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $1.30, with estimates from $1.28 to $1.32 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $1.57, with estimates from $1.36 to $1.82 from 3 analysts.
What revenue do analysts expect from Ironwood Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $493.63M, with estimates from $489.10M to $497.80M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $504.23M, with estimates from $470.30M to $530.60M.
How many analysts cover IRWD?
4 analysts rate Ironwood Pharmaceuticals stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
IRWD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors